<unk>  is a interleukin-6 (IL-6) receptor antagonist that is FDA approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include neutropenia, increased ALT, injection site erythema, upper respiratory infections and urinary tract infections.
Sarilumab
Nebacumab
Burosumab
Dupilumab
Evolocumab
Alirocumab
Secukinumab
Lanadelumab